Ifosfamide-based chemotherapy for previously treated lung cancer patients

Yuh Min Chen, Jacqueline Ming Liu, Ming Fang Wu, Hsiao Wei Wu, Wei Chun Lin, Chun Ming Tsai, Reury Perng Perng, Jacqueline Whang-Peng

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background. Ifosfamide-based chemotherapy has already been the basis of three separate clinical trials. In this study, ifosfamide was administered to lung cancer patients who had failed to respond to previous chemotherapy, to assess its response rate and toxicity. Methods. From January 1993 to December 1996, 21 patients were treated, including eight patients with small cell lung cancer (SCLC) and 13 with non-small cell lung cancer (NSCLC). Patients who had histocytologically confirmed lung cancer, were previously treated with chemotherapy, had a measurable lesion(s), were younger than 75 years of age, had an Eastern Cooperative Oncology Group performance status of 0-3 and adequate marrow, renal and liver function were eligible for inclusion in this study. For SCLC patients, ifosfamide 2.4 g/m2 intravenous (IV) infusion was given over 30 minutes on days 1-3 every four weeks. For NSCLC, two regimens were used: IFL (ifosfamide 2 g/m2, 5-fluorouracil (FU) 600 mg/m2 and leucovorin 50 mg/m2 IV infusion on days 1-3 every four weeks) and LIFE (leucovorin 50 mg/m2, ifosfamide 1 g/m2, 5-FU 400 mg/m2 and epirubicin 12 mg/m2 IV infusion on days 1-3 every four weeks). For NSCLC patients, IFL was used for the first two years of treatment and LIFE was used in the last two treatment years. All patients were evaluated for treatment response and toxicity. Results. The major toxic effect, myelosuppression (grade 3 or 4 leukopenia), occurred in 62.5% of SCLC patients and 23.1% of NSCLC patients during treatment, and in 6215% and 10% of SCLC and NSCLC patients, respectively, throughout the course. Only one SCLC and one NSCLC patient experienced febrile neutropenia. One toxic death, attributed to febrile neutropenia, was documented in a patient with SCLC. Alopecia was ubiquitous. Other toxicities were uncommon and mild. The overall response rate was 50% in SCLC and 7.7% in NSCLC. The median time to disease progression was 61 days in SCLC and 47 days in NSCLC. Median survival was 172 days in SCLC and 173 days in NSCLC. Conclusions. The study results suggest that ifosfamide chemotherapy is active with an acceptable toxicity profile in previously treated SCLC patients. However, it lacks efficacy in NSCLC patients who have been previously treated.

Original languageEnglish
Pages (from-to)389-396
Number of pages8
JournalChinese Medical Journal (Taipei)
Volume61
Issue number7
Publication statusPublished - Jul 1 1998
Externally publishedYes

Fingerprint

Ifosfamide
Lung Neoplasms
Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
Drug Therapy
Intravenous Infusions
Febrile Neutropenia
Leucovorin
Poisons
Fluorouracil
Epirubicin
Alopecia
Leukopenia
Therapeutics
Disease Progression

Keywords

  • Chemotherapy
  • Ifosfamide
  • Lung cancer

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Chen, Y. M., Liu, J. M., Wu, M. F., Wu, H. W., Lin, W. C., Tsai, C. M., ... Whang-Peng, J. (1998). Ifosfamide-based chemotherapy for previously treated lung cancer patients. Chinese Medical Journal (Taipei), 61(7), 389-396.

Ifosfamide-based chemotherapy for previously treated lung cancer patients. / Chen, Yuh Min; Liu, Jacqueline Ming; Wu, Ming Fang; Wu, Hsiao Wei; Lin, Wei Chun; Tsai, Chun Ming; Perng, Reury Perng; Whang-Peng, Jacqueline.

In: Chinese Medical Journal (Taipei), Vol. 61, No. 7, 01.07.1998, p. 389-396.

Research output: Contribution to journalArticle

Chen, YM, Liu, JM, Wu, MF, Wu, HW, Lin, WC, Tsai, CM, Perng, RP & Whang-Peng, J 1998, 'Ifosfamide-based chemotherapy for previously treated lung cancer patients', Chinese Medical Journal (Taipei), vol. 61, no. 7, pp. 389-396.
Chen YM, Liu JM, Wu MF, Wu HW, Lin WC, Tsai CM et al. Ifosfamide-based chemotherapy for previously treated lung cancer patients. Chinese Medical Journal (Taipei). 1998 Jul 1;61(7):389-396.
Chen, Yuh Min ; Liu, Jacqueline Ming ; Wu, Ming Fang ; Wu, Hsiao Wei ; Lin, Wei Chun ; Tsai, Chun Ming ; Perng, Reury Perng ; Whang-Peng, Jacqueline. / Ifosfamide-based chemotherapy for previously treated lung cancer patients. In: Chinese Medical Journal (Taipei). 1998 ; Vol. 61, No. 7. pp. 389-396.
@article{97689dc1281244ad968f6266f83f29a4,
title = "Ifosfamide-based chemotherapy for previously treated lung cancer patients",
abstract = "Background. Ifosfamide-based chemotherapy has already been the basis of three separate clinical trials. In this study, ifosfamide was administered to lung cancer patients who had failed to respond to previous chemotherapy, to assess its response rate and toxicity. Methods. From January 1993 to December 1996, 21 patients were treated, including eight patients with small cell lung cancer (SCLC) and 13 with non-small cell lung cancer (NSCLC). Patients who had histocytologically confirmed lung cancer, were previously treated with chemotherapy, had a measurable lesion(s), were younger than 75 years of age, had an Eastern Cooperative Oncology Group performance status of 0-3 and adequate marrow, renal and liver function were eligible for inclusion in this study. For SCLC patients, ifosfamide 2.4 g/m2 intravenous (IV) infusion was given over 30 minutes on days 1-3 every four weeks. For NSCLC, two regimens were used: IFL (ifosfamide 2 g/m2, 5-fluorouracil (FU) 600 mg/m2 and leucovorin 50 mg/m2 IV infusion on days 1-3 every four weeks) and LIFE (leucovorin 50 mg/m2, ifosfamide 1 g/m2, 5-FU 400 mg/m2 and epirubicin 12 mg/m2 IV infusion on days 1-3 every four weeks). For NSCLC patients, IFL was used for the first two years of treatment and LIFE was used in the last two treatment years. All patients were evaluated for treatment response and toxicity. Results. The major toxic effect, myelosuppression (grade 3 or 4 leukopenia), occurred in 62.5{\%} of SCLC patients and 23.1{\%} of NSCLC patients during treatment, and in 6215{\%} and 10{\%} of SCLC and NSCLC patients, respectively, throughout the course. Only one SCLC and one NSCLC patient experienced febrile neutropenia. One toxic death, attributed to febrile neutropenia, was documented in a patient with SCLC. Alopecia was ubiquitous. Other toxicities were uncommon and mild. The overall response rate was 50{\%} in SCLC and 7.7{\%} in NSCLC. The median time to disease progression was 61 days in SCLC and 47 days in NSCLC. Median survival was 172 days in SCLC and 173 days in NSCLC. Conclusions. The study results suggest that ifosfamide chemotherapy is active with an acceptable toxicity profile in previously treated SCLC patients. However, it lacks efficacy in NSCLC patients who have been previously treated.",
keywords = "Chemotherapy, Ifosfamide, Lung cancer",
author = "Chen, {Yuh Min} and Liu, {Jacqueline Ming} and Wu, {Ming Fang} and Wu, {Hsiao Wei} and Lin, {Wei Chun} and Tsai, {Chun Ming} and Perng, {Reury Perng} and Jacqueline Whang-Peng",
year = "1998",
month = "7",
day = "1",
language = "English",
volume = "61",
pages = "389--396",
journal = "Journal of the Chinese Medical Association",
issn = "1726-4901",
publisher = "Elsevier Taiwan LLC",
number = "7",

}

TY - JOUR

T1 - Ifosfamide-based chemotherapy for previously treated lung cancer patients

AU - Chen, Yuh Min

AU - Liu, Jacqueline Ming

AU - Wu, Ming Fang

AU - Wu, Hsiao Wei

AU - Lin, Wei Chun

AU - Tsai, Chun Ming

AU - Perng, Reury Perng

AU - Whang-Peng, Jacqueline

PY - 1998/7/1

Y1 - 1998/7/1

N2 - Background. Ifosfamide-based chemotherapy has already been the basis of three separate clinical trials. In this study, ifosfamide was administered to lung cancer patients who had failed to respond to previous chemotherapy, to assess its response rate and toxicity. Methods. From January 1993 to December 1996, 21 patients were treated, including eight patients with small cell lung cancer (SCLC) and 13 with non-small cell lung cancer (NSCLC). Patients who had histocytologically confirmed lung cancer, were previously treated with chemotherapy, had a measurable lesion(s), were younger than 75 years of age, had an Eastern Cooperative Oncology Group performance status of 0-3 and adequate marrow, renal and liver function were eligible for inclusion in this study. For SCLC patients, ifosfamide 2.4 g/m2 intravenous (IV) infusion was given over 30 minutes on days 1-3 every four weeks. For NSCLC, two regimens were used: IFL (ifosfamide 2 g/m2, 5-fluorouracil (FU) 600 mg/m2 and leucovorin 50 mg/m2 IV infusion on days 1-3 every four weeks) and LIFE (leucovorin 50 mg/m2, ifosfamide 1 g/m2, 5-FU 400 mg/m2 and epirubicin 12 mg/m2 IV infusion on days 1-3 every four weeks). For NSCLC patients, IFL was used for the first two years of treatment and LIFE was used in the last two treatment years. All patients were evaluated for treatment response and toxicity. Results. The major toxic effect, myelosuppression (grade 3 or 4 leukopenia), occurred in 62.5% of SCLC patients and 23.1% of NSCLC patients during treatment, and in 6215% and 10% of SCLC and NSCLC patients, respectively, throughout the course. Only one SCLC and one NSCLC patient experienced febrile neutropenia. One toxic death, attributed to febrile neutropenia, was documented in a patient with SCLC. Alopecia was ubiquitous. Other toxicities were uncommon and mild. The overall response rate was 50% in SCLC and 7.7% in NSCLC. The median time to disease progression was 61 days in SCLC and 47 days in NSCLC. Median survival was 172 days in SCLC and 173 days in NSCLC. Conclusions. The study results suggest that ifosfamide chemotherapy is active with an acceptable toxicity profile in previously treated SCLC patients. However, it lacks efficacy in NSCLC patients who have been previously treated.

AB - Background. Ifosfamide-based chemotherapy has already been the basis of three separate clinical trials. In this study, ifosfamide was administered to lung cancer patients who had failed to respond to previous chemotherapy, to assess its response rate and toxicity. Methods. From January 1993 to December 1996, 21 patients were treated, including eight patients with small cell lung cancer (SCLC) and 13 with non-small cell lung cancer (NSCLC). Patients who had histocytologically confirmed lung cancer, were previously treated with chemotherapy, had a measurable lesion(s), were younger than 75 years of age, had an Eastern Cooperative Oncology Group performance status of 0-3 and adequate marrow, renal and liver function were eligible for inclusion in this study. For SCLC patients, ifosfamide 2.4 g/m2 intravenous (IV) infusion was given over 30 minutes on days 1-3 every four weeks. For NSCLC, two regimens were used: IFL (ifosfamide 2 g/m2, 5-fluorouracil (FU) 600 mg/m2 and leucovorin 50 mg/m2 IV infusion on days 1-3 every four weeks) and LIFE (leucovorin 50 mg/m2, ifosfamide 1 g/m2, 5-FU 400 mg/m2 and epirubicin 12 mg/m2 IV infusion on days 1-3 every four weeks). For NSCLC patients, IFL was used for the first two years of treatment and LIFE was used in the last two treatment years. All patients were evaluated for treatment response and toxicity. Results. The major toxic effect, myelosuppression (grade 3 or 4 leukopenia), occurred in 62.5% of SCLC patients and 23.1% of NSCLC patients during treatment, and in 6215% and 10% of SCLC and NSCLC patients, respectively, throughout the course. Only one SCLC and one NSCLC patient experienced febrile neutropenia. One toxic death, attributed to febrile neutropenia, was documented in a patient with SCLC. Alopecia was ubiquitous. Other toxicities were uncommon and mild. The overall response rate was 50% in SCLC and 7.7% in NSCLC. The median time to disease progression was 61 days in SCLC and 47 days in NSCLC. Median survival was 172 days in SCLC and 173 days in NSCLC. Conclusions. The study results suggest that ifosfamide chemotherapy is active with an acceptable toxicity profile in previously treated SCLC patients. However, it lacks efficacy in NSCLC patients who have been previously treated.

KW - Chemotherapy

KW - Ifosfamide

KW - Lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0031904740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031904740&partnerID=8YFLogxK

M3 - Article

C2 - 9699391

AN - SCOPUS:0031904740

VL - 61

SP - 389

EP - 396

JO - Journal of the Chinese Medical Association

JF - Journal of the Chinese Medical Association

SN - 1726-4901

IS - 7

ER -